« Return to News | R&D Trends

Drug discovery industry in midst of 'profound change'

Thursday, June 2, 2011 12:50 PM

Drug makers are "defining a new contract with society" as they overhaul their R&D, according to the former head of the sector's trade body.

Richard Barker, who last week left the Association of the British Pharmaceutical Industry after six years at the helm, told The Daily Telegraph that the industry was "in the midst of a profound change."

"We're moving progressively from a model where most of the large companies did most of their research and development internally to an innovation ecosystem model," he said. "So it becomes increasingly important for the large companies to work closely with universities, research charities and small and medium-sized enterprises in the discovery adventure."

As drugmakers look to drive a better return on their research investment and shore up their pipelines, they have pared their in-house discovery and, in some cases, sought consolidation.

Barker said this was likely to continue, but added, "Mergers solve some problems, but not others. For example, they can make better use of commercial infrastructure. What it doesn't do is improve research and development productivity. What improves productivity is some of the new approaches, an ability or willingness to redesign the development process."

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.